For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.
Rs 23,000 crore outflows! Is the September FII rout indicating a worse end to 2026?
Foreign investors have resumed selling Indian equities in September, with FPI outflows crossing Rs 23,000 crore through September 19. Higher crude prices, elevated US bond